Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331 - PubMed (original) (raw)

Clinical Trial

doi: 10.1002/pbc.31856. Epub 2025 Jun 14.

Affiliations

Clinical Trial

Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331

Jennifer A Belsky et al. Pediatr Blood Cancer. 2025 Sep.

Abstract

Background: CHIPS (Childhood Hodgkin International Prognostic Score), a predictive score for event-free-survival (EFS), was originally developed using factors presenting at diagnosis in patients with intermediate-risk Hodgkin lymphoma (HL). Prospective validation of CHIPS in patients was a pre-specified aim of AHOD1331, a trial comparing brentuximab-vedotin, doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (Bv-AVEPC) to standard ABVE-PC (and response-adapted radiation) in children with high-risk HL.

Methods: AHOD1331 was a multicenter randomized phase 3 study. Patients were aged 2-21 years with untreated stages IIB+bulk, IIIB, IV HL. CHIPS was determined by assigning one point each for: Stage IV disease, large mediastinal adenopathy (greater than one-third thoracic diameter), albumin (<3.5 g/dL), and fever (T ≥ 38°C). Associations between CHIPS, baseline patient, and disease characteristics were tested. The validity of CHIPS to predict EFS was evaluated by both overall and within pre-specified subgroups defined by treatment arm, PET2 response, and disease stage.

Results: The four CHIPS components were analyzable in 576 of the 587 eligible patients. Distribution of CHIPS did not differ by study treatment arm (p = 0.158). CHIPS was significantly prognostic for EFS in this high-risk cohort (p = 0.008) and was independently predictive of EFS regardless of treatment arm, PET2 response, or stage. In subset analyses, CHIPS remained independently prognostic among patients with PET2 rapid responding lesions (RRL; p = 0.021) or Stage IVB disease (p = 0.047).

Conclusion: CHIPS were predictive of EFS in patients with high-risk HL treated on AHOD1331. CHIPS may aid in the allocation of patients to risk-based treatment algorithms, and can serve as an effective, inexpensive, and feasible proxy for more biologically based factors.

Keywords: cancer biology; hematology/oncology; hodgkin's disease; oncology; pediatric oncology; prediction modeling in cancer.

© 2025 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest Statement: Dr. Castellino receives funding support and or advisement to/from Pfizer (formally SeaGen Inc, BMS-Pediatric Scientific Advisory Board, Lymphoma Research Foundation Scientific Advisory Board, the Leukemia Lymphoma Society Board of Directors and an R50 CA285492-01. Dr. Kelly reported grants from the National Cancer Institute during the conduct of the study; grants from Merck, nonfinancial support from Bristol Meyers Squibb and Seagen (both provide study drug for an NCI-funded trial), and grants from the Department of Defense outside the submitted work. Dr. Belsky advises for Bristol Meyers Squibb.

References

    1. Kelly K Hodgkin lymphoma in children and adolescents: improving the therapeutic index. Blood 2015;126:2452–2458. (In English). DOI: 10.1182/blood-2015-07-641035. -DOI -PubMed
    1. Belsky JA, Hochberg J, Giulino-Roth L. Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults. Best Pract Res Clin Haematol 2023;36(1):101445. (In eng). DOI: 10.1016/j.beha.2023.101445. -DOI -PubMed
    1. Castellino SM, Pei Q, Parsons SK, et al. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma. New England Journal of Medicine 2022;387(18):1649–1660. DOI: 10.1056/NEJMoa2206660. -DOI -PMC -PubMed
    1. Singh D, Vaccarella S, Gini A, De Paula Silva N, Steliarova-Foucher E, Bray F. Global patterns of Hodgkin lymphoma incidence and mortality in 2020 and a prediction of the future burden in 2040. International Journal of Cancer 2022;150(12):1941–1947. DOI: 10.1002/ijc.33948. -DOI -PubMed
    1. Ehrhardt MJ, Flerlage JE, Armenian SH, Castellino SM, Hodgson DC, Hudson MM. Integration of Pediatric Hodgkin Lymphoma Treatment and Late Effects Guidelines: Seeing the Forest Beyond the Trees. J Natl Compr Canc Netw 2021;19(6):755–764. (In eng). DOI: 10.6004/jnccn.2021.7042. -DOI -PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources